| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/21/2008 | US20080199422 Method for the Treatment of Myelodysplastic Syndromes Using 1-Oxo-2-(2,6-Dioxopiperidin-3-Yl-)-4-Methylisoindoline |
| 08/21/2008 | DE102007008484A1 Pharmazeutische Zubereitung zur Bekämpfung von Metastasen Pharmaceutical composition for controlling metastases |
| 08/21/2008 | DE10100462B4 Verfahren zur Herstellung von Dialysekonzentrat und Behälter und Vorrichtung zur Durchführung des Verfahrens A process for producing dialysis concentrate and container and apparatus for carrying out the method |
| 08/21/2008 | CA2678436A1 Serpine1 polymorphisms are predictive of response to activated protein c administration and risk of death |
| 08/21/2008 | CA2678127A1 Tgf-beta stimulant and further agent to reduce side effects |
| 08/21/2008 | CA2677842A1 Pharmaceutical composition comprising microparticle oily suspension |
| 08/21/2008 | CA2677769A1 Therapeutic agent for urinary excretion disorder |
| 08/21/2008 | CA2677715A1 Use of chitosans to increase nail growth rate |
| 08/21/2008 | CA2677703A1 Methods of correcting imbalance between bone resorption and bone formation and kits and compositions therefor |
| 08/21/2008 | CA2676259A1 Use of chitosans for the treatment of nail inflammatory diseases |
| 08/21/2008 | CA2674773A1 Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury |
| 08/21/2008 | CA2673573A1 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 08/20/2008 | EP1959013A1 Human circulating virus inhibitory peptide (VRIP) and its use |
| 08/20/2008 | EP1958966A2 Methods for modulating T cell responses by manipulating a common cytokine receptor gamma chain |
| 08/20/2008 | EP1958956A2 Peptidomimetic protease inhibitors |
| 08/20/2008 | EP1958647A1 Pharmaceutical composition with bacteria for tumor treatment |
| 08/20/2008 | EP1958642A1 Regulation of cell growth by MUC1 |
| 08/20/2008 | EP1958639A1 Use of chitosans for the treatment of nail inflammatory diseases |
| 08/20/2008 | EP1958638A1 Use of chitosans to increase nail growth rate |
| 08/20/2008 | EP1957509A2 Methods and compositions for the treatment of gastrointestinal disorders |
| 08/20/2008 | EP1957109A2 Modulators of cdc2-like kinases (clks) and methods of use thereof |
| 08/20/2008 | EP1957087A1 Compositions for external application, containing adenosyl cobalamin for improvement of skin diseases |
| 08/20/2008 | EP1957061A1 Methods for the treatment of muscle loss |
| 08/20/2008 | EP1896077A4 Methods and compositions for the prevention and treatement of inflammatory disease |
| 08/20/2008 | EP1765083A4 Use of il-17 in the treatment of fertility-related disorders |
| 08/20/2008 | EP1737438B1 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome |
| 08/20/2008 | EP1523336B1 Targeted agents for nerve regeneration |
| 08/20/2008 | EP1509618B1 Autoimmune conditions and nadph oxidase defects |
| 08/20/2008 | EP1509205B1 Pharmaceutical composition having a delayed active substance release and method for the preparation thereof |
| 08/20/2008 | EP1499284B1 Biologically active compounds for the modification of bodily odours |
| 08/20/2008 | EP1482976B1 A preparation and method for weight reduction |
| 08/20/2008 | EP1459765B1 6-fluorobicyclo 3.1.0 hexane derivatives |
| 08/20/2008 | EP1446500B1 A method for regulating immune function in primates using the foxp3 protein |
| 08/20/2008 | EP1424071B1 Perfume compositions |
| 08/20/2008 | EP1387681B1 Use of castanospermine derivatives for the treatment of hepatitis c |
| 08/20/2008 | EP1333850B1 Use of il-13 inhibitors for the treatment of tumors |
| 08/20/2008 | EP1247103B1 Tethered ligands and methods of use |
| 08/20/2008 | EP1240823B1 N-calcium channel knockout animal |
| 08/20/2008 | EP1198589B1 Tenascin-c nucleic acid ligands |
| 08/20/2008 | EP1075493B1 Dna encoding snorf25 receptor |
| 08/20/2008 | EP1033985B2 Stable ascorbic acid preparation for topical use |
| 08/20/2008 | EP0883404B1 Combination therapy for osteoporosis |
| 08/20/2008 | EP0705111B1 Agent with influences hyperactive immunological effector cells |
| 08/20/2008 | CN101247832A Pharmaceutical preparation containing an angiotensin II receptor antagonist and a calcium channel blocker |
| 08/20/2008 | CN101247831A A method for modulating hla class II tumor cell surface expression with a cytokine mixture |
| 08/20/2008 | CN101247810A Combination of a hypnotic agent and R(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof |
| 08/20/2008 | CN101247795A Methods and compositions for treatment of CNS disorders |
| 08/20/2008 | CN101245058A Inhibitors of aspartyl protease |
| 08/20/2008 | CN101244275A Long-acting sustained-release medicaments for treating and renovating bone disease and preparation thereof |
| 08/20/2008 | CN101244272A Anti-solid tumors pharmaceutical combination containing topological enzyme inhibitor |
| 08/20/2008 | CN101244271A Anti-solid tumors pharmaceutical combination containing topological enzyme inhibitor |
| 08/20/2008 | CN101244262A Medicament combination preparation for treating bacterial infection |
| 08/20/2008 | CN101244067A Application of 23-hydroxyl radical betulic acid in preparing reversal agent multidrug resistance of cancer cell |
| 08/20/2008 | CN101244062A Sustained release pharmaceutical compositions and methods of treatment using the same |
| 08/20/2008 | CN101244039A Novel method for preparing indissoluble medicaments liposome preparations |
| 08/20/2008 | CN101244036A High dispersion does type containing cholesterol group phosphoryl nucleoside analogue |
| 08/20/2008 | CN101244034A Sustained-release agent containing taxone and its synergistic agent |
| 08/20/2008 | CN101244033A Sustained-release agent containing taxone and its synergistic agent |
| 08/20/2008 | CN101244030A Anticancer sustained-release injection containing estrogen receptor antagon |
| 08/20/2008 | CN101244029A Anticancer sustained-release injection containing estrogen receptor antagon |
| 08/20/2008 | CN100411686C Visual function improving agents |
| 08/20/2008 | CN100411628C Combination of sterically hindered platinum coordination compound and no-platinum anticarcinogen, and use thereof |
| 08/20/2008 | CN100411620C Use of dipyridazole or mopidamol in the manufacture of a medicament for treatment and prevention of fibrin-dependent microcirculation disorders |
| 08/20/2008 | CN100411618C Use of compounds that are effective as selective opiate receptor modulators |
| 08/20/2008 | CN100411617C Use of flavone compounds in preparing medicament |
| 08/19/2008 | US7415302 Method and system for leading macromolecule substances into living target cells |
| 08/19/2008 | US7414122 host cell, viral vector; agonists and antagonists; diagnosis or treatment of cancer; antiproliferative; infertility, miscarriage, preterm labor and delivery, and endometriosis; immunosuppressants; vaccine adjuvants; genetic mapping |
| 08/19/2008 | US7414058 Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
| 08/19/2008 | US7414046 Gyrase inhibitors and uses thereof |
| 08/19/2008 | US7414039 Interstitial therapy for immediate symptom relief and chronic therapy in interstitial cystitis |
| 08/19/2008 | US7414024 B-cell differentiation factor (il-6); anticancer agents; antisense agents; monoclonal antibody |
| 08/19/2008 | US7414020 DNA expression vector; host cell transformed, transfected or infected with the vector; transgenic cell, tissue or organism; HCDS1 protein |
| 08/19/2008 | US7413850 Uses of carbamoyl phosphate synthetase for the diagnois of inflammatory diseases and sepsis |
| 08/19/2008 | US7413751 Methods of treatment using a gastric retained losartan dosage |
| 08/19/2008 | US7413748 comprises patches for improved dosage |
| 08/19/2008 | US7413728 Immune modulator |
| 08/19/2008 | CA2434906C Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| 08/19/2008 | CA2432799C Pyrazole compounds useful as protein kinase inhibitors |
| 08/19/2008 | CA2370003C A composition and method for the enhancement of the efficacy of drugs |
| 08/19/2008 | CA2282682C Tazarotene and corticosteroid treatment for psoriasis |
| 08/19/2008 | CA2205134C A method for treating vascular headaches |
| 08/19/2008 | CA2120731C Methods of improving allograft or xenograft tolerance by administration of an lfa-3 or cd2 binding protein |
| 08/14/2008 | WO2008097861A2 MODULATION OF NEUROGENESIS WITH BIGUANIDES AND GSK3-ß AGENTS |
| 08/14/2008 | WO2008096777A1 Therapeutic agent for irritable bowel syndrome |
| 08/14/2008 | WO2008096769A1 Pharmaceutical compositions containing substituted cercosporamide derivatives |
| 08/14/2008 | WO2008096122A2 Progesterone for the prevention of preterm birth |
| 08/14/2008 | WO2008077939A3 Duloxetine composition |
| 08/14/2008 | WO2008075149A3 Ophthalmic compositions of parasympathetic stimulants and anti-inflammatories for use in the treatment of presbyopia |
| 08/14/2008 | WO2008068217A3 Pharmaceutical composition comprising a coated hmg-coa reductase inhibitor and an inhibitor of the renin-angiotensin system |
| 08/14/2008 | WO2008044054A3 Hydroxy-substituted benzoic acid amide compounds for use in therapy |
| 08/14/2008 | WO2008028903A3 Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| 08/14/2008 | WO2007132359A3 Composition containing lactobacillus sp. and a cannabinoid receptor and/or a opioid receptor agonist |
| 08/14/2008 | WO2007112414A3 Conjugated double strand compositions for use in gene modulation |
| 08/14/2008 | WO2007066189A3 Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
| 08/14/2008 | US20080194711 determining the level of expression of chemokine receptor (CX3CR1) genes or protein expression in natural killer cells; reduction of the relative expression is indicative of nervous system disorders; medical diagnosis |
| 08/14/2008 | US20080194697 ethyl endcapped hepta- and nona-tetramethylenediamines and 1,2-bis(4-(ethylamino)butylaminomethyl)cyclopropane, used for treating prostate cancer, prostatitis and benign prostatic hyperplasia |
| 08/14/2008 | US20080194683 Medicament for preventing and/or treating peripheral neuropathies |
| 08/14/2008 | US20080194515 Extracting DNA from a blood or buccal cell sample, PCR, resolution, and identification of differences in sequences between the extracted DNA and PCR primers; drug screening |
| 08/14/2008 | US20080194469 Biodrug such as eptifibatide with blend of a hydrolyzable hydrophobic polymer containing diphenolic tyrosine monomer such as poly(desaminotyrosyltyrosine hexyl ester adipate (Poly(DTH adipate)), and another less hydrophobic hydrolyzable polymer that degrades to form acidic groups, releasing the biodrug |
| 08/14/2008 | US20080194023 Generating vascular smooth muscle cells in vitro from ES cells |